Nanexa AB (publ) (NANEXA.ST)
SEK 2.54
(-5.22%)
SEK 2.54
(-5.22%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.03 Million SEK | -35.71% |
| 2022 | 6.27 Million SEK | 63.67% |
| 2021 | 3.83 Million SEK | -1.39% |
| 2020 | 3.88 Million SEK | -24.62% |
| 2019 | 5.15 Million SEK | -11.45% |
| 2018 | 5.82 Million SEK | 66.14% |
| 2017 | 3.5 Million SEK | 83.17% |
| 2016 | 1.91 Million SEK | 444.3% |
| 2015 | 351.46 Thousand SEK | 0.43% |
| 2014 | 349.96 Thousand SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.53 Million SEK | -15.95% |
| 2024 Q1 | 1.83 Million SEK | -54.59% |
| 2023 Q2 | 2.96 Million SEK | -15.67% |
| 2023 Q4 | 4.03 Million SEK | 66.96% |
| 2023 FY | 4.03 Million SEK | -35.71% |
| 2023 Q1 | 3.51 Million SEK | -43.93% |
| 2023 Q3 | 2.41 Million SEK | -18.58% |
| 2022 Q2 | 5.66 Million SEK | 145.64% |
| 2022 Q3 | 4.55 Million SEK | -19.64% |
| 2022 FY | 6.27 Million SEK | 63.67% |
| 2022 Q4 | 6.27 Million SEK | 37.73% |
| 2022 Q1 | 2.3 Million SEK | -39.8% |
| 2021 Q3 | 2.88 Million SEK | -13.33% |
| 2021 Q1 | 2.59 Million SEK | -33.32% |
| 2021 Q2 | 3.33 Million SEK | 28.6% |
| 2021 FY | 3.83 Million SEK | -1.39% |
| 2021 Q4 | 3.83 Million SEK | 32.69% |
| 2020 Q4 | 3.88 Million SEK | 24.99% |
| 2020 FY | 3.88 Million SEK | -24.62% |
| 2020 Q2 | 3.36 Million SEK | -7.35% |
| 2020 Q1 | 3.63 Million SEK | -29.49% |
| 2020 Q3 | 3.1 Million SEK | -7.69% |
| 2019 Q2 | 4.43 Million SEK | -5.84% |
| 2019 Q3 | 4.15 Million SEK | -6.21% |
| 2019 FY | 5.15 Million SEK | -11.45% |
| 2019 Q4 | 5.15 Million SEK | 24.04% |
| 2019 Q1 | 4.7 Million SEK | -19.16% |
| 2018 Q3 | 2.55 Million SEK | -17.28% |
| 2018 FY | 5.82 Million SEK | 66.14% |
| 2018 Q1 | 3.1 Million SEK | -11.36% |
| 2018 Q2 | 3.09 Million SEK | -0.52% |
| 2018 Q4 | 5.82 Million SEK | 127.77% |
| 2017 Q4 | 3.5 Million SEK | 9.47% |
| 2017 FY | 3.5 Million SEK | 83.17% |
| 2017 Q3 | 3.2 Million SEK | -0.31% |
| 2017 Q2 | 3.21 Million SEK | 78.29% |
| 2017 Q1 | 1.8 Million SEK | -5.86% |
| 2016 FY | 1.91 Million SEK | 444.3% |
| 2016 Q1 | 252 Thousand SEK | -28.3% |
| 2016 Q2 | 245 Thousand SEK | -2.78% |
| 2016 Q4 | 1.91 Million SEK | 714.05% |
| 2016 Q3 | 235 Thousand SEK | -4.08% |
| 2015 FY | 351.46 Thousand SEK | 0.43% |
| 2015 Q3 | 313 Thousand SEK | 4.33% |
| 2015 Q4 | 351.46 Thousand SEK | 12.29% |
| 2015 Q2 | 300 Thousand SEK | 0.0% |
| 2015 Q1 | - SEK | -100.0% |
| 2014 FY | 349.96 Thousand SEK | 0.0% |
| 2014 Q4 | 349.96 Thousand SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 8.8 Million SEK | 54.182% |
| Enzymatica AB (publ) | 26.1 Million SEK | 84.553% |
| Enorama Pharma AB (publ) | 436 Thousand SEK | -824.771% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | 18.93 Million SEK | 78.703% |
| Moberg Pharma AB (publ) | 4.73 Million SEK | 14.883% |
| Newbury Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 473.8 Million SEK | 99.149% |
| Probi AB (publ) | 53.79 Million SEK | 92.505% |
| Swedencare AB (publ) | 1.65 Billion SEK | 99.757% |
| Swedish Orphan Biovitrum AB (publ) | 20.48 Billion SEK | 99.98% |
| Toleranzia AB | 850 Thousand SEK | -374.353% |
| Vivesto AB | 8.16 Million SEK | 50.637% |